Anti-Inflammatory Mechanisms of the Annexin A1 Protein and Its Mimetic Peptide Ac2-26 in Models of Ocular Inflammation in Vivo and in Vitro
Nenhuma Miniatura disponível
Data
2013-06-01
Autores
Girol, Ana Paula [UNIFESP]
Mimura, Kallyne Kioko Oliveira [UNIFESP]
Drewes, Carine Cristiane
Boonheis, Simone M.
Solito, Egle
Farsky, Sandra Helena Poliselli
Gil, Cristiane Damas [UNIFESP]
Oliani, Sonia Maria [UNIFESP]
Orientadores
Tipo
Artigo
Título da Revista
ISSN da Revista
Título de Volume
Resumo
Annexin A1 (AnxAl) is a protein that displays potent anti-inflammatory properties, but its expression in eye tissue and its role in ocular inflammatory diseases have not been well studied. We investigated the mechanism of action and potential uses of AnxAl and its mimetic peptide (Ac2-26) in the endotoxin-induced uveitis (EIU) rodent model and in human ARPE-19 cells activated by LPS. in rats, analysis of untreated EIU after 24 and 48 h or EIU treated with topical applications or with a single s.c. injection of Ac2-26 revealed the anti-inflammatory actions of Ac2-26 on leukocyte infiltration and on the release of inflammatory mediators; the systemic administration of Boc2, a formylated peptide receptor (fpr) antagonist, abrogated the peptide's protective effects. Moreover, AnxA1(-/-) mice exhibited exacerbated EIU compared with wild-type animals Immunohistochemical studies of ocular tissue showed a specific AnxAl posttranslational modification in EIU and indicated that the fpr2 receptor mediated the anti-inflammatory actions of AnxAl. in vitro studies confirmed the roles of AnxAl and fpr2 and the protective effects of Ac2-26 on the release of chemical mediators in ARPE-19 cells. Molecular analysis of NF-kappa B translocation and IL-6, IL-8, and cyclooxygenase-2 gene expression indicated that the protective effects of AnxAl occur independently of the NF-kappa B signaling pathway and possibly in a posttranscriptional manner. Together, our data highlight the role of AnxAl in ocular inflammation, especially uveitis, and suggest the use of AnxAl or its mimetic peptide Ac2-26 as a therapeutic approach.
Descrição
Citação
Journal of Immunology. Bethesda: Amer Assoc Immunologists, v. 190, n. 11, p. 5689-5701, 2013.